Format

Send to

Choose Destination
Cardiovasc Res. 2020 Feb 5. pii: cvaa027. doi: 10.1093/cvr/cvaa027. [Epub ahead of print]

Promise of Autologous CD34+ Stem/Progenitor Cell Therapy for Treatment of Cardiovascular Disease.

Author information

1
Department of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
2
The Christ Hospital Health Network/The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH, USA.
3
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
4
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN USA.

Abstract

CD34+ cells are hematopoietic stem cells used therapeutically in patients undergoing radiation or chemotherapy due to their regenerative potential and ability to restore the hematopoietic system. In animal models, CD34+ cells have been associated with therapeutic angiogenesis in response to ischemia. Several trials have shown the potential safety and efficacy of CD34+ cell delivery in various cardiovascular diseases. Moreover, Phase III trials have now begun to explore the potential role of CD34+ cells in treatment of both myocardial and peripheral ischemia. CD34+ cells have been shown to be safe and well-tolerated in the acute myocardial infarction, heart failure, and angina models. Several studies have suggested potential benefit of CD34+ cell therapy in patients with coronary microvascular disease as well. In this review we will discuss the therapeutic potential of CD34+ cells, and describe the pertinent trials that have used autologous CD34+ cells in no-options refractory angina, acute myocardial infarction, and heart failure. Lastly, we will review the potential utility of autologous CD34+ cells in coronary endothelial and microvascular dysfunction.

KEYWORDS:

Acute Coronary Syndromes; CD34+; Cardiovascular Diseases; Coronary Endothelial Dysfunction; Coronary Microvascular Dysfunction; Endothelial Progenitor Cells; Heart Failure; Refractory Angina

PMID:
32022845
DOI:
10.1093/cvr/cvaa027

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center